Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation. B, K., N, K., Ns, Y., Lm, C., B, G., A, A., Sb, E., G, O., A, O., E, K., Ta, C., M, G., & S, B. January, 2021. ISSN: 1573-2592 Publisher: J Clin Immunol
Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation [link]Paper  doi  abstract   bibtex   
Our findings suggest that improved disease management and immune dysregulatory profile can be achieved with ruxolitinib treatment before transplantation and this would be beneficial to reduce the risk of adverse outcome of HSCT.
@misc{b_stepwise_2021,
	title = {Stepwise {Reversal} of {Immune} {Dysregulation} {Due} to {STAT1} {Gain}-of-{Function} {Mutation} {Following} {Ruxolitinib} {Bridge} {Therapy} and {Transplantation}},
	url = {https://pubmed.ncbi.nlm.nih.gov/33475942/},
	abstract = {Our findings suggest that improved disease management and immune dysregulatory profile can be achieved with ruxolitinib treatment before transplantation and this would be beneficial to reduce the risk of adverse outcome of HSCT.},
	language = {en},
	urldate = {2021-02-08},
	journal = {Journal of clinical immunology},
	author = {B, Kayaoglu and N, Kasap and Ns, Yilmaz and Lm, Charbonnier and B, Geckin and A, Akcay and Sb, Eltan and G, Ozturk and A, Ozen and E, Karakoc-Aydiner and Ta, Chatila and M, Gursel and S, Baris},
	month = jan,
	year = {2021},
	pmid = {33475942},
	doi = {10.1007/s10875-020-00943-y},
	note = {ISSN: 1573-2592
Publisher: J Clin Immunol},
	keywords = {CES, Clinical Exome, SOPHiA DDM},
}
Downloads: 0